G1 Therapeutics Inc $ 23.18 0.11 (0.48%)
Volume:
1,642,079
Avg Vol (1m):
1,721,484
Market Cap $:
964.02 Mil
Enterprise Value $:
784.47 Mil
PE Ratio:
0.00
PB Ratio:
4.91
Financial Strength | 6/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 7.47 | ||
| Equity-to-Asset | 0.78 | ||
| Debt-to-Equity | 0.16 | ||
| Debt-to-EBITDA | -0.29 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 8.5 | ||
| Beneish M-Score | 0 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -213.04 | ||
| Net Margin % | -219.18 | ||
| ROE % | -46.66 | ||
| ROA % | -38.72 | ||
| ROC (Joel Greenblatt) % | -821.19 | ||
| 3-Year EBITDA Growth Rate | 9 | ||
| 3-Year EPS without NRI Growth Rate | 9.8 |
GTHX
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 4.91 | ||
| PS Ratio | 19.25 | ||
| EV-to-EBIT | -8.11 | ||
| EV-to-EBITDA | -8.16 | ||
| EV-to-Revenue | 17.34 | ||
| Current Ratio | 9.23 | ||
| Quick Ratio | 9.23 | ||
| Days Sales Outstanding | 1.91 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.1 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 4.93 | ||
| Earnings Yield (Greenblatt) % | -12.36 |